GDC-0084
|
|
|
- CAS-Nr.
- 1382979-44-3
- Englisch Name:
- GDC-0084
- Synonyma:
- Paxalisib;RG7666;CS-2290;RG-7666;GDC-0084;RG 7666);GDC-0084(RG7666);GDC-0084 (GDC0084;GDC-0084 (Paxalisib;Paxalisib (GDC-0084)
- CBNumber:
- CB93123145
- Summenformel:
- C18H22N8O2
- Molgewicht:
- 382.42
- MOL-Datei:
- 1382979-44-3.mol
|
GDC-0084 Eigenschaften
- Dichte
- 1.60±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- L?slichkeit
- insoluble in H2O; insoluble in EtOH; ≥2.83 mg/mL in DMSO with ultrasonic
- Aggregatzustand
- Solid
- pka
- 2.62±0.40(Predicted)
- Farbe
- White to off-white
- InChI
- InChI=1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21)
- InChIKey
- LGWACEZVCMBSKW-UHFFFAOYSA-N
- SMILES
- C1(N)=NC=C(C2N=C(N3CCOCC3)C3=C(N=2)N2CCOC(C)(C)C2=N3)C=N1
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
|
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
|
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
GDC-0084 Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
GDC-0084 is an inhibitor of phosphoinositide 3-kinase (PI3K) and mTOR (1,2). Inhibitors of PI3K are useful compounds for developing treatments for brain tumors.
synthetische
Stumpf et al. at Genentech Inc. (Roche group) developed an efficient multikilogram process to synthesize the brain penetrant PI3K inhibitor, GDC\0084, a potential drug candidate for the treatment of several brain cancers. An efficient Suzuki coupling reaction between a chloropyrimidine and an arylboronic ester using a palladium catalyst at low loading was reported. The optimized conditions were demonstrated on 6.75 kg of a chloropyrimidine intermediate, providing 7.49 kg of crude GDC\0084 (94% yield, 99.4% HPLC purity). Using the commercially available XPhos Pd G2 catalyst, instead of the usual PdCl2(dppf)·CH2Cl2 catalyst, it was possible to reduce the catalyst loading from 2 to 0.5 mol%. A final scavenging/recrystallization combination from Si\Thiol (a solid\supported resin) and acetic acid/water provided the crude GDC\0084 with the required purity and polymorphic form (off\white solid, 6.41 kg, 83% yield, 99.7% HPLC purity).
Genentech’s route to GDC\0084 employing a pivotal Suzuki reaction.
GDC-0084 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
GDC-0084 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 122)Lieferanten
- GDC-0084
- 5-[8,9-Dihydro-6,6-dimethyl-4-(4-morpholinyl)-6H-[1,4]oxazino[4,3-e]purin-2-yl]-2-pyrimidinamine
- 5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[4,3-e]purin-2-yl)pyrimidin-2-amine
- 2-Pyrimidinamine, 5-[8,9-dihydro-6,6-dimethyl-4-(4-morpholinyl)-6H-[1,4]oxazino[4,3-e]purin-2-yl]-
- 5-[6,6-Dimethyl-4-(4-morpholinyl)-8,9-dihydro-6H-[1,4]oxazino[4,3-e]purin-2-yl]-2-pyrimidinamine
- GDC-0084(RG7666)
- CS-2290
- GDC-0084 (GDC0084
- RG 7666)
- RG7666
- RG-7666
- RG7666; RG-7666; RG 7666; GDC-0084; GDC0084; GDC 0084
- GDC-0084;GDC 0084;RG7666;RG-7666;RG 7666
- Paxalisib (GDC-0084)
- GDC-0084 (Paxalisib
- Paxalisib, GDC-0084, RG7666
- GDC-0084|||RG7666|||GDC 0084
- GDC0084, 10 mM in DMSO
- Paxalisib
- 1382979-44-3
